DEA Greenlights Weed Imports for Natural Products Research Lab
Published Date: 12/22/2025
Notice
Summary
The National Center for Natural Products Research wants to become an official importer of certain controlled substances, including marijuana. People and companies involved can share their thoughts or ask for a hearing by January 21, 2026. This move could impact how these substances are brought into the U.S., but no costs or fees are mentioned yet.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
University Seeks Importer Registration
On September 8, 2025, the National Center for Natural Products Research applied to be registered to import marihuana (drug code 7360, Schedule I) and tetrahydrocannabinols (drug code 7370, Schedule I) for research and manufacturing. The application says the center plans to acquire new genetic materials with different cannabinoid profiles for research and manufacturing purposes.
Import Approval Excludes Finished Drugs
The DEA notice says any authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale. The registration is limited to the activities authorized under 21 U.S.C. 952(a)(2).
Stakeholders Can Comment by Jan 21, 2026
Registered bulk manufacturers of the affected drug classes and other applicants may submit electronic comments or objections through regulations.gov, or request a hearing, on or before January 21, 2026. Hearing requests must also be mailed to the DEA hearing clerk at the Springfield, Virginia addresses listed in the notice.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2025-23502, Texas Eastern Transmission, L.P.; Notice of Scoping Period Requesting Comments on Environmental Issues for the Proposed Kosciusko Compressor Station Replacement Project
Texas Eastern Transmission wants to replace a compressor station in Attala County, Mississippi, and the government is asking the public for their thoughts on how this might affect the environment. If you live nearby or care about nature, now’s the time to speak up before January 15, 2026. This project could change local air and land conditions, so your input helps decide if it moves forward safely and smartly.
Next: 2025-23504, Agency Information Collection Activities: Program Analysis and Evaluation (PA&E) Office, Stakeholder Engagement Division (SED) Convenings Evaluation
The Cybersecurity and Infrastructure Security Agency (CISA) wants your thoughts on a new survey to see how well their meetings with partners are working. This helps them improve how they gather feedback and make decisions. If you’re involved or interested, you’ve got until January 21, 2026, to share your ideas—no cost, just a few minutes of your time!